AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results - Daver, N; Vyas, P; Kambhampati, S; Malki, MA; Larson, R; Asch, A; Mannis, G; Chai-Ho, W; Tanaka, T; Bradley, T; Jeyakumar, D; Wang, E; et al. (Elsevier, 2022)